https://goo.gl/qYqijm
Although all major treatment classes reviewed in a Cochrane meta-analysis were more effective than placebo for moderate to severe psoriasis, biologic agents appeared to be the most efficacious.
The researchers found that all of the anti-IL17 drugs and guselkumab (Tremfya) were more effective than the anti-TNF alpha drugs infliximab (Remicade), adalimumab (Humira), and etanercept (Enbrel) for reaching PASI 90 status.
Ustekinumab (Stelara, an IL-12/23 inhibitor) was better than etanercept but there was no clear difference between infliximab, adalimumab, and etanercept. Tofacitinib (Xeljanz, a small molecule) was superior to methotrexate (a conventional systemic agent), but there was no difference between the other small molecules and conventional drugs.